“We have seen that cladribine therapy is effective in reducing inflammatory activity and on the progression of long-term disability, essentially presenting no surprises from a safety point of view”. These are the words of Claudio Gasperini, medical director of the Neuroscience department, Aou San Camillo-Forlanini of Rome Francesco Patti, professor of Neurology, University of Catania on the sidelines of the first of the two days of 'Space of care: as one for patients', the event organized in Milan by the global pharmaceutical company Merck and dedicated to new therapeutic frontiers for the treatment of highly active relapsing multiple sclerosis, among which cladribine in tablets stands out.
#Multiple #sclerosis #Gasperini #Cladribine #effective #reducing #longterm #disability #progression
